MHRA approves vimseltinib for adults with TGCT in UK

On 14 August 2026, the Medicines and Healthcare products Regulatory Agency, or MHRA, approved vimseltinib, sold as Romvimza, for adults with tenosynovial giant cell tumour, known as TGCT. According to the MHRA announcement, the medicine can be used when the tumour is affecting movement or when surgery is not a realistic option. That may sound like a very specialist decision, but it matters because rare conditions are often poorly understood outside clinics. For patients, families and anyone trying to make sense of a diagnosis, this approval adds something practical: another treatment route for a condition that can be painful, limiting and difficult to live with.

If you have never heard of TGCT, you are not alone. TGCT is a rare, non-cancerous tumour that forms around a joint and its tendons. The MHRA says it usually affects one joint rather than several, and it is most often seen in the knee or ankle of young and middle-aged adults. **What this means:** non-cancerous does not mean harmless. TGCT can still cause pain, swelling, stiffness and trouble moving normally. A person may not be dealing with cancer, but they may still be dealing with a condition that changes how they walk, work, study, exercise or simply get through an ordinary day.

For some people with TGCT, surgery is used to remove the tumour. But surgery is not always possible, and it is not always the right answer if the tumour is in a difficult place or if the effects of an operation could be too great. That is why the wording of this approval matters. The medicine is meant for adults whose movement is affected or who are unsuitable for surgery. **What it means for patients:** this is not a blanket approval for everyone with joint pain or every kind of tumour. It is a targeted decision for a specific group of adults with TGCT, and treatment choices will still depend on a specialist’s judgement about symptoms, risks and what is likely to help most.

The active ingredient, vimseltinib, works by blocking the proteins that help these tumours grow. In plain English, the aim is to slow the process that is driving the tumour rather than simply easing symptoms for a short time. That is why the drug has drawn attention as a new option for people who cannot rely on surgery. The MHRA says Romvimza comes as a capsule and should be swallowed whole with water, with or without food, twice a week. That detail may seem small, but it is part of safe use. Medicines only work as expected when people get clear instructions and can follow them.

There is also a useful lesson here about how medicines approval works in the UK. The MHRA granted the new marketing authorisation to Deciphera Pharmaceuticals on 14 August 2026. The agency says the product was submitted and approved through the International Recognition Procedure, Route B. **How to read that:** the UK regulator can use an existing decision from another trusted regulator as part of the route to approval, while still making its own judgement for the UK. The MHRA’s role, as it explains in the announcement, is to check that a medicine works and is acceptably safe, and that its benefits outweigh its risks.

One phrase in the MHRA notice deserves extra attention: vimseltinib is under additional monitoring. That does not mean the medicine has been found unsafe. It means regulators want especially careful reporting as more people begin using it in real-world settings. This is one way medicine safety keeps being checked after approval, not just before it. The same notice says vimseltinib should not be used in pregnancy. It also lists common side effects that may affect more than 1 in 5 people, including tiredness, swelling around the eyes, ankles and feet, itching, rashes, high blood pressure, raised liver enzymes, higher cholesterol, higher creatinine levels and reduced neutrophils, which are a type of white blood cell.

For anyone prescribed the medicine, the practical advice is straightforward. Take vimseltinib exactly as prescribed, and speak to a doctor, pharmacist or nurse about any side effects. The MHRA also asks people to report suspected side effects through the Yellow Card scheme, because patient reporting helps spot patterns that may not show up immediately in trials. If you want the full technical detail, the MHRA says the Summary of Product Characteristics and the Patient Information Leaflet will be published on its products website within seven days of approval. **What this means:** the headline is not that TGCT suddenly has a cure. The real news is that adults facing a rare and mobility-limiting tumour now have another approved option in the UK, and that option will be watched closely as evidence grows.